Comparison of Gastrointestinal Complications of Paracetamol and Ibuprofen in the Management of Infants with Patent Ductus Arteriosus: A Randomized Clinical Trial Study

Abstract

Background: Patent ductus arteriosus (PDA) is one of the more common congenital heart defects in preterm neonates. The closure of PDA can be done with ibuprofen; however, this drug is associated with many contraindications and potential side-effects. In the past years, paracetamol has been proposed for the treatment of PDA. This study was designed to evaluate the efficacy and gastrointestinal complications of paracetamol and ibuprofen for the pharmacological closure of PDA in preterm infants.

Methods: In a clinical trial study, 40 preterm infants with echocardiographically confirmed PDA were randomly assigned to receive either paracetamol (n = 23; 15 mg/kg every 6 h for 2 days) or ibuprofen (n = 17; initial dose of 10 mg/kg, followed by 5 mg/kg every 12 h for 2 days). The neonates matched for gestational age and weight. We used t-test for parametric, Chi-square for categorical, and Wilcoxon for nonparametric variables. Significant level was considered less than 0.05.

Results: Platelet count, BUN and creatinine levels, and closure of PDA had not significant difference between two groups (P > 0.05). Incidence and severity of GI bleeding, feeding intolerance, and NEC were significantly more in infants who received paracetamol than ibuprofen (P < 0.05).

Conclusions: There were no differences in the rate of PDA closure between the two drugs, but with respect to complications, rate and severity of GI bleeding, feeding intolerance, and NEC were not significantly in more infants who received paracetamol than ibuprofen. Therefore, paracetamol could not be used as a proper alternative agent for ibuprofen in the treatment of PDA in preterm infants.

Keywords: Acetaminophen, ductus arteriosus, ibuprofen, patent

Introduction

Patent ductus arteriosus (PDA) is a heart defect in which there is a persistent connection between the aorta and the pulmonary arteries.[1] It can also cause low diastolic pressure that leads to other conditions such as necrotizing enterocolitis (NEC), intraventricular hemorrhage, retinopathy of prematurity, periventricular leukomalacia, and renal failure.[2,3] It is common in premature neonates and infants following maternal rubella during pregnancy.[4] PDA accounts for 2%–7% of all heart abnormality in the united states.[5] In Iran, the prevalence of PDA has been reported approximately 15% of all congenital heart defects.[6]

There are currently three approaches in PDA treatment including fluid intake restriction, drug therapy, and surgical method. Conservative therapy involves restricting fluid intake, which may be associated with the administration of diuretics. In this method, 34% of cases, PDA is closed within 3 to 6 days.[7] In surgical repair, PDA closure is performed by ligation or a combination of ligation and use of surgical clips or stitches.[8] The most important drugs in PDA treatment are nonselective COX inhibitors including indomethacin and ibuprofen, with success rates of 75% to 93%. Both of these drugs are injected through intravenous because of decreased gastric perfusion and gastrointestinal complications. Both drugs also are associated with nervous system complications, necrotizing enterocolitis, and reducing cerebral and mesenteric blood flow.[9,12] However, they are less common in ibuprofen administration; it may cause bleeding, skin lesions, hypoglycemia, hypocalcemia, heart failure, respiratory failure, IVH, and renal dysfunction.[13] Recently, oral or IV administration of paracetamol

Address for correspondence: Dr. Navid Danaei, Department of Pediatric, Semnan University of Medical Science, Semnan, Iran. E-mail: drdanai@gmail.com

Access this article online
Website: www.ipvmjournall.net/www.ipvm.ir
DOI: 10.4103/ipvm.IJPVM_387_19
Quick Response Code: How to cite this article: Shahmirzadi G, Nooripour S, Ziai A, Danaei N. Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: A randomized clinical trial study. Int J Prev Med 2021;12:48.

Gohar Shahmirzadi1,2, Shamsollah Nooripour1, Abbas Ziai3, Navid Danaei1
1Department of Pediatric, Semnan University of Medical Science, Semnan, Iran
2Students Research Committee, Semnan University of Medical Science, Semnan, Iran
3Social Determinants of Health Research Center, Semnan University of Medical Science, Semnan, Iran

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. For reprints contact: reprints@medknow.com
(acetaminophen) has been considered in the treatment of PDA, which is first recommended by Terrin et al. (2016). In many studies, it has been defined as a safe, effective and with less side effects than other conventional antiinflammatory drugs in PDA closure. However, routine use of that has been limited due to some side effects including transiently increase in hepatic enzymes, acute hepatic toxicity, retinopathy of prematurity, gastrointestinal bleeding, necrotizing enterocolitis, pulmonary hemorrhage, IVH, sepsis, and death. Hence, the best treatment option for PDA drug therapy is still controversial.

Several studies indicated that the overall complication rate for PDA treatment with acetaminophen is lower than other drugs. Results of other studies suggest that there is no difference in the incidence of complications in neonates treated with acetaminophen or ibuprofen. Some studies also recommend further studies, while pointing out the efficacy of acetaminophen, which has proven to be superior to other conventional PDA drug therapies.

This study aimed to evaluate the efficacy and gastrointestinal complications of acetaminophen and ibuprofen for the pharmacological closure of PDA in preterm infants.

Methods

In this clinical trial study, all premature neonates with diagnosis of PDA who born at Amiralmomenin Hospital, Semnan, Iran between May 2018 and May 2019 were included in the study. Ethical approval was obtained for this study from the Ethics Committee of the Semnan University of Medical Sciences.

Inclusion criteria were the age of less than 14 days at the time of diagnosis and hospitalizing in neonates intensive care unit during follow-up of the patients. In addition, neonates with congenital heart defects that maintaining the openness of the ductus is vital for them such as pulmonary atresia and major or chromosomal congenital abnormalities, history of nonsteroidal antiinflammatory use during pregnancy, persistent pulmonary hypertension in the neonates (PPHN), 5-min Apgar score <5, having PDA symptom and need for supplementary treatment (in control group), presence of vomiting or hematemesis in first three days of birth, and G6PD deficiency were excluded from the study.

The patients were selected through convenience sampling and then were randomly divided into two groups of paracetamol and ibuprofen by block permuted randomization. Patients in two groups homogenized in terms of weight and gestational age at delivery time. In paracetamol group, in the first 24 h of birth, 15 mg/kg paracetamol at six-hour intervals for 48 h was injected intravenously. Patients in ibuprofen group orally received 10 mg/kg at first day of birth and then followed by 5 mg/kg at next 48 h.

Data collection was done by a questionnaire and were gender, birth weight, gestational age at delivery, type of delivery, and single or multiple pregnancy. Ultrasonic cardiogram platelet count, BUN, serum creatinine, and potential blood in the stool were evaluated before and after 3 days of taking first dose of drugs. In addition, the incidence of NEC, OB, and feeding intolerance were recorded using medical records of patients. The diagnosis of NEC was confirmed by the presence of gas or air bubbles in the wall of the intestine on an abdominal X-ray and symptoms such as inability to tolerate feeding, bloody stools, and distention of the abdomen. OB test was performed through checking stool samples for occult blood. In addition, PDA was diagnosed, if in echocardiography, the ratio of the left atrium to the aortic root was greater than 1.3 mm and the internal duct diameter was more than 1.5 mm.

Data obtained were analyzed using SPSS version 22 software (IBM Corporation, Armonk, NY, USA). The t-test was used to compare the normally distributed data, whereas the Wilcoxon’s test was used to compare the nonnormally distributed data. In addition, Chi-square test was used for test the association between categorical variables. The level of statistical significance was set at P value <0.05.

Results

In this study, neonates with diagnosis of PDA were evaluated at two groups of paracetamol (n = 23) and ibuprofen (n = 17). The mean of neonatal gestational age was 30.43 ± 4.28 weeks in paracetamol group and 32.29 ± 3.25 weeks in the ibuprofen group. The mean of neonatal weight was 1566.73 ± 752.84 g in paracetamol group and 1773.05 ± 663.05 g in neonates receiving ibuprofen. In addition, the mean of hospitalization group was 23.00 ± 18.88 days in the paracetamol group and 17.64 ± 12.50 days in the ibuprofen group.

The mean of first minute Apgar scores was 6.3 ± 2.7 and 7.7 ± 2.2, in paracetamol and ibuprofen groups, respectively. Table 1 shows history of preeclampsia and gestational diabetes and death of neonates during the study.

Data analysis showed that there was no significant difference between pre and posttreatment in PLT count, and creatinine and BUN levels in the two groups receiving paracetamol and ibuprofen (P < 0.05) [Table 2].

There was no statistically significant relationship between PDA closure and type of treatment (paracetamol and ibuprofen) (P < 0.05) [Table 3].

Feeding intolerance and NEC were significantly higher in paracetamol group than ibuprofen group (P > 0.05). Table 4 shows the complications of both treatments.

Discussion

In this study, there was no significant difference between the paracetamol and ibuprofen groups in platelet count and
In our study, the closure of PDA was 94% in the paracetamol group (n=23) and 94% in the ibuprofen group (n=17) (P=0.179). In addition, in this study, there were no significant differences between the two groups in drug side effects and other clinical complications (P=0.611). In the study of Habibi et al., the PDA closure was 87.5% (n=28) in the paracetamol group and 75.7% in the ibuprofen group (n=23), which was significantly different (P=0.179). In our study, there was a higher incidence of feeding intolerance and NEC between groups, indicating ibuprofen is a preferred treatment option in our study.

In contrast to the finding of the current study, in which side effects of paracetamol were lower than ibuprofen in PDA closure.

In the study of Habibi et al., the incidence of complications was 95% in the paracetamol group and 94% in the ibuprofen group. In our study, there was a significant difference in gastrointestinal bleeding and feeding intolerance between groups, indicating ibuprofen is a preferred treatment option in our study.

The results of a meta-analysis study by Souvik et al. indicated that high doses of oral ibuprofen may increase the risk of death and complications such as enterocolitis; however, it may increase PDA closure compared to standard doses of intravenous ibuprofen or intravenous treatment.
indomethacin and paracetamol.\textsuperscript{15} In the Ohlsson and Shah study, the incidence of complications was lower in the paracetamol than ibuprofen.\textsuperscript{14} In addition, Dani \textit{et al.} reported that incidence of complications in the two groups receiving paracetamol and ibuprofen was not significantly different and the same therapeutic efficacy was obtained for both drugs and paracetamol was suggested as a suitable drug for PDA treatment.\textsuperscript{17} In the study of Al-lawama \textit{et al.}, there was no statistically significant difference in short-term neonatal outcomes in the both drug therapies.\textsuperscript{20}

The results of Yang \textit{et al.} study also indicated the same rate of DA closure ($P = 0.506$) and the same complications such as oliguria, blood in stool, intraventricular hemorrhage, NEC, and bronchopulmonary dysplasia in the paracetamol and ibuprofen groups.\textsuperscript{35} However, in Yang \textit{et al.}, both drugs were administered orally, whereas in our study paracetamol was injected and ibuprofen was administered orally. El-Mashad \textit{et al.} also indicated, there was no significant difference in PDA closure in paracetamol, indomethacin, and ibuprofen groups ($P = 0.868$), which is similar to the results of our study. Furthermore, serum creatinine and BUN increased significantly in the ibuprofen and indomethacin groups ($P < 0.001$) and there was a significant decrease in platelet count and urinary output in both the ibuprofen and indomethacin groups ($P < 0.001$).\textsuperscript{36} This is opposite with the results in our study since no significant differences were found in platelet count, creatinine, and BUN between the two groups.

The limitation of our study was the low sample size. Thus, it is recommended to conduct a multicenter study with a larger sample size of neonates with PDA. In addition, it is recommended studies aimed to compare different drugs with different administration methods (orally and injectable).

\textbf{Conclusions}

The rate of closure of PDA with paracetamol administration was not different from that of oral ibuprofen. In addition, the incidence of complications was higher in paracetamol than ibuprofen administration.

\textbf{Financial support and sponsorship}

Nil.

\textbf{Conflicts of interest}

There are no conflicts of interest.

\textbf{Received: 03 Nov 19 Accepted: 09 Dec 19 Published: 26 May 21}

\textbf{References}

1. Schneider D, Moore J. Arteriosus P ductus. Patent ductus arteriosus. Circulation 2006;114:1873-82.

2. Allen HD, Driscoll DJ, Shaddy RE, Feltes TF. Moss and Adams’ Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. Lippincott Williams and Wilkins; 2013. ISBN 97 8-1-4511-1893-3 (hardback).

3. Mann D, Zipes D, Libby P, Bonow R. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Single Volume. Philadelphia: Elsevier/Saunders; 2014.

4. Kliegman RM, Behrman RE, Jenson HB, Stanton BM. Nelson Textbook of Pediatrics E-book. Elsevier Health Sciences; 2007.

5. Mani A, Meraji S-M, Houshyar R, Radhakrishnan J, Mani A, Ahangar M, \textit{et al.} Finding genetic contributions to sporadic disease: A recessive locus at 12q24 commonly contributes to patent ductus arteriosus. Proc Natl Acad Sci 2002;99:15054-9.

6. Pourarian S, Farahbaksh N, Sharma D, Cheriki S, Bijanzadeh F. Prevalence and risk factors associated with the patency of ductus arteriosus in premature neonates: A prospective observational study from Iran. J Maternal-Fetal Neonatal Med 2017;30:1460-4.

7. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006;117:1113-21.

8. Dice JE, Bhatia J. Patent ductus arteriosus: An overview. J Pediatr Pharmacol Ther 2007;12:138-46.

9. Aranda J, Thomas R, editors. Systematic Review: Intravenous Ibuprofen in Preterm Newborns. Semin Perinatol 2006;30:114-20. Elsevier.

10. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999;135:733-8.

11. Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997;131:549-54.

12. Noriopour S, Molaei A, Bandari R, Emadi A, Far SM, Forozeshfard M. Comparison of the results of simultaneous surfactant administration and nasal continuous positive airway pressure (INSURE) and non-administration of surfactant for the treatment of infants with respiratory distress syndrome. J Compr Pediatr 2017;8:e37462.

13. Poon G, editor. Ibuprofen Lysine (NeoProfen) for the Treatment of Patent Ductus Arteriosus. Baylor University Medical Center Proceedings; 2007: Taylor and Francis.

14. Terrin G, Conte F, Oncel MY, Scipione A, McNamara PJ, Simons S, \textit{et al.} Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: A systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2016;101:F127-36.

15. Mitra S, Florez ID, Tamayo ME, Aune D, Mbuagbaw L, Veroniki A-A, \textit{et al.} Effectiveness and safety of treatments used for the management of patent ductus arteriosus (PDA) in preterm infants: A protocol for a systematic review and network meta-analysis. BMJ Open 2016;6:e011271.

16. Bagheri MM, Niknafs P, Sabsevari F, Torabi MH, Bisari BB, Noroozi E, \textit{et al.} Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iran J Pediatr 2016;26:e3975.

17. Dani C, Poggi C, Mosca F, Schena F, Lista G, Ramenghi L, et al. Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: Study protocol for a randomized control trial. Trials 2016;17:182.

18. Dash SK, Kabra NS, Avasthi BS, Sharma SR, Padhi P, Ahmed J. Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: A randomized controlled trial. Indian Pediatr 2015;52:573-8.

19. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H.
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: A randomized controlled trial. PloS One 2013;8:e77888.

20. Oncel MY, Erdeve O. Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World J Clin Pediatr 2016;5:75.

21. Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S. Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Neonatology 2013;104:168.

22. Dart RC, Rumack BH. Intravenous acetaminophen in the United States: Iatrogenic dosing errors. Pediatrics 2012;129:349-53.

23. Nevin D, Shung J. Intravenous paracetamol overdose in a preterm infant during anesthesia. Pediatr Anesh 2010;20:105-7.

24. Isbister G, Bucens I, Whyte I. Paracetamol overdose in a preterm neonate. Arch Dis Child Fetal Neonatal Ed 2001;85:F70-2.

25. Porta R, Sánchez L, Nicolás M, García C, Martínez M. Lack of toxicity after paracetamol overdose in a extremely preterm neonate. Eur J Clin Pharmacol 2012;68:901-2.

26. Al-lawama M, Alammori I, Abdelghani T, Badran E. Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. J Int Med Res 2018;46:811-8.

27. Habibi M, Nobakht M, Pirbazari TJ, Yazdi Z. The effect of oral ibuprofen and oral acetaminophen in the patent ductus arteriosus (PDA) in preterm infants born in Kousvar hospital of Qazvin (a comparative study). WJPMR 2016;2:203-7.

28. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med 2011;364:255-64.

29. Kim BSM, Li BT, Engel A, Samra JS, Clarke S, Norton ID, et al. Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. World J Gastrointest Pathophysiol 2014;5:467.

30. De Carolis MP, Romagnoli C, Polimeni V, Piersigilli F, Zecca E, Papacci P, et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr 2000;159:364-8.

31. Dani C, Bertini G, Reali M, Murr P, Fabris C, Vangi V, et al. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr 2000;89:1369-74.

32. Oncel MY, Yurtutan S, Erdeve O, Uras N, Altug N, Oguz SS, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: A randomized controlled trial. J Pediatr 2014;164:510-4. e1.

33. Sinha R, Negi V, Dalal S. An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol 2013;2:30-2.

34. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev 2018;4:CD010061.

35. Yang B, Gao X, Ren Y, Wang Y, Zhang Q. Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: A randomized controlled trial. Exp Ther Med 2016;12:2531-6.

36. El-Mashad AE-R, El-Mahdy H, El Amrousy D, Elgendy M. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. Eur J Pediatr 2017;176:233-40.